Intellia To Take On Pfizer Blockbuster With Gene-Editing Therapy
Aims To Challenge Vyndaqel
After achieving a landmark in gene-editing with NTLA-2001, Intellia moves to expand its reach into a larger market.
You may also be interested in...
New data show that a high dose of Intellia’s in vivo CRISPR-Cas9 based therapy is safe and effective for up to six months, which could unlock a new era in genetic disease treatment.
The company presented 18-month data at a conference that it thinks will support strong uptake. European regulators required the 18-month data for filing; an FDA decision based on 9-month data is expected in April.
The news desert over the holidays meant that any Phase III clinical study announcement would be closely examined. Unfortunately, BridgeBio’s shock Phase III failure was made worse by elusive explanations.